BridgeBio Pharma Inc

For the period ended Mar 31, 2025. Filed Apr 29, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 29, 2025

BBIO$77.93+4.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	Three Months Ended March 31,
	2025	2024
Revenues:
License and services revenue	$79,894	$211,120
Net product revenue	36,739	—
Total revenues, net	116,633	211,120
Operating costs and expenses:
Cost of revenues:
Cost of license and services revenue	605	598
Cost of goods sold	2,034	—
Total cost of revenues	2,639	598
Research and development	111,431	140,972
Selling, general and administrative	106,365	65,807
Restructuring, impairment and related charges	570	3,400
Total operating costs and expenses	221,005	210,777
Income (loss) from operations	(104,372)	343
Other income (expense), net:
Interest income	5,385	4,075
Interest expense	(42,141)	(23,471)
Loss on extinguishment of debt	(21,155)	(26,590)
Net loss from equity method investments	(15,556)	—
Other income (expense), net	8,231	9,483
Total other income (expense), net	(65,236)	(36,503)
Net loss	(169,608)	(36,160)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	2,186	944
Net loss attributable to common stockholders of BridgeBio	$(167,422)	$(35,216)
Net loss per share attributable to common stockholders of BridgeBio, basic and diluted	$(0.88)	$(0.20)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted	190,145,253	178,705,310

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.